Biophytis S.A. (BPTSY)

Biophytis S.A.: A Comprehensive Overview (As of November 1, 2023)

Company Profile

History and Background:

Biophytis S.A. is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Paris, France. The company focuses on developing and bringing to market innovative drugs targeting age-related diseases with unmet medical needs.

Core Business Areas:

• Muscle Wasting Diseases: Biophytis is exploring the use of its lead candidate, Sarconeos, for various muscle-wasting conditions, including sarcopenia, cachexia, and Duchenne muscular dystrophy.
• Vascular Aging and Fibrosis: The company is researching the therapeutic potential of its anti-aging compound, RejuvenAge, for vascular aging and fibrosis-related conditions.

Leadership Team and Corporate Structure:

The current leadership team includes:

• Stanislas Veillet (CEO)
• Dr. François-M. Létard (Chief Medical Officer)
• Yann Godfrin (Chief Financial Officer)

Biophytis has a Board of Directors composed of professionals with extensive experience in the pharmaceutical and biotech industry.

Top Products and Market Share:

Main Products:

• Sarconeos: This drug candidate aims to treat age-related muscle loss. It has recently completed a Phase III trial in sarcopenia and is currently under investigation for other muscle-wasting conditions.
• RejuvenAge: This compound targets vascular aging and fibrosis. Preclinical studies have shown promising results in improving vascular function and reducing fibrosis.

Market Share:

As of November 2023, Biophytis is still in the clinical trial phase for its lead candidate, Sarconeos. Therefore, it does not have any marketed products or market share. However, the potential market for muscle-wasting diseases like sarcopenia is estimated to be substantial, reaching 589 million individuals globally by 2040.

Product Performance and Market Reception:

Data from the Phase III trial of Sarconeos in sarcopenia is expected in early 2024. These results will be crucial in determining the drug's future market reception and potential market share.

Total Addressable Market:

The global market for muscle-wasting diseases is estimated to reach US$10.81 billion by 2028. The market for treatments against vascular aging and fibrosis is also anticipated to grow significantly in the coming years.

Financial Performance:

• Revenue: As a pre-commercial company, Biophytis currently has no product revenues.
• Net Income: As of the first half of 2023, the company reported a net loss of €3.7 million.
• Profit Margins: Currently, Biophytis has no profits.
• Earnings per Share (EPS): With no current profitability, Biophytis has a negative EPS.

Financial Health:

• Cash Flow: Biophytis has limited operational cash flow and relies heavily on financing activities for working capital.
• Balance Sheet: The company's balance sheet includes a substantial amount of cash and cash equivalents, along with liabilities, mainly due to long-term and short-term borrowings.

Dividends and Shareholder Returns:

Biophytis has not paid any dividends to date and does not anticipate paying dividends in the foreseeable future as a pre-commercial company.

Growth Trajectory:

The company's growth is largely dependent on the successful development and commercialization of its drug candidates. The projected market size of the target therapeutic areas suggests potential for significant growth if successful.

Market Dynamics:

Biophytis operates in the highly competitive pharmaceutical industry, facing established players and numerous research entities focused on similar therapeutic areas. The industry landscape remains dynamic with continuous technological advancements and regulatory changes. Biophytis needs to demonstrate successful clinical trials, achieve regulatory approval, and develop effective commercialization strategies to gain a solid position in the market.

Key Competitors:

Major competitors in the field of muscle-wasting diseases include:

• Orexigen Therapeutics
• Raptor Pharmaceuticals
• Protagonist Therapeutics
• Check (CHCK)
• OREX (OREX)

In the vascular aging and fibrosis areas, key competitors include:

• Athersys (ATHX)
• Verve Therapeutics (VERV)
• Caladrius Biosciences (CLBS)

Potential Challenges and Opportunities:

Challenges:

• Difficulty in achieving successful outcomes in clinical trials and obtaining regulatory approval.
• Intense competition from established players.
• Raising enough capital to continue and fund research and development.
• Regulatory hurdles and pricing pressure in entering major markets like the US.

Opportunities:

• Large and growing market for therapeutic areas addressed by Biophytis' pipeline.
• Potential for strategic partnerships for drug development and commercialization.
• Positive clinical data demonstrating the efficacy and safety of Biophytis' products.

Recent Acquisitions:

Biophytis has not reported any acquisitions over the past 3 years (2020 - 2023).

AI-Based Fundamental Rating:

Assigning a definitive AI-based rating for Biophytis is challenging at this stage. The lack of commercialized products and limited financial data restrict robust AI analysis. However, considering factors like pipeline potential, market size, and competitive landscape, a preliminary AI-based rating could potentially fall in the range of 4-6 out of 10. This reflects the company's early-stage development and dependence on future clinical and commercial milestones for significant advancement.

Disclaimer:

This overview is based on publicly available information as of November 1, 2023. Please note that this information may change over time. This overview is for informational purposes only and should not be considered as investment advice.

Additional Information:

For further information and up-to-date information on Biophytis S.A., please refer to the following sources:

• Website: https://www.biophytis.com/en/

Disclaimer: This information is intended as a general overview only and should not be considered as investment advice. Please consult with a qualified financial advisor before making any investment decisions.